home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9602.ZIP
/
M9620353.TXT
< prev
next >
Wrap
Text File
|
1996-02-26
|
1KB
|
26 lines
Document 0353
DOCN M9620353
TI The NCI's AIDS antiviral drug screening program.
DT 9602
AU Yang SS; Antiviral Evaluation Branch, National Cancer Institute,
Bethesda,; MD 20892, USA.
SO Leukemia. 1995 Oct;9 Suppl 1:S9-11. Unique Identifier : AIDSLINE
MED/96022211
AB The Developmental Therapeutics Program (DTP) in the National Cancer
Institute has an unique mission by serving as a resource for all
academic and private research institutions, the National Institutes of
Health in the USA, and the global scientific community in the quest for
effective therapeutic agents for treating patients with Acquired Immune
Deficiency Syndrome (AIDS) as well as for cancer patients. This
communication will concentrate on the developmental therapeutic program
on anti-AIDS drug discovery.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY Antiviral
Agents/*TOXICITY Cell Fusion Cell Survival/DRUG EFFECTS Drug
Screening/*METHODS Human HIV/*DRUG EFFECTS HIV Infections/*DRUG
THERAPY HIV-1/*DRUG EFFECTS/PHYSIOLOGY *National Institutes of Health
(U.S.) United States Virus Replication/DRUG EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).